Science & Technology · 22 Jul 2026

Qdenga dengue vaccine

Consider the following pairs: List I (Term/Entity) List II (Correct Description) 1. Drug Controller General of India A. Approved Qdenga as India's first dengue vaccine 2. Biological E B. Indian manufacturing partner targeting 50 million annual doses 3. Antibody-Dependent Enhancement C. Phenomenon where prior infection worsens a subsequent infection with a different serotype 4. Tetravalent design D. Trains immunity against a single dengue serotype only How many of the above pairs are correctly matched?

AOnly one pair
BOnly two pairs
COnly three pairs
DAll four pairs
This question is based on: India's First Dengue Vaccine: Why Approval Is Only Half the Story
Take this in full test mode → Instructions for 22 Jul 2026
About this question

Why in news

The DCGI approved Qdenga (TAK-003) for ages 4-60, India's first dengue vaccine, to be manufactured domestically through a partnership with Biological E.

Why for UPSC

UPSC often tests vaccine science concepts (like tetravalent design or ADE) alongside the regulatory and manufacturing entities behind a newly approved product - a classic Sci-Tech pattern linking concept to current event.

Prelims summary

Qdenga, India's first DCGI-approved dengue vaccine, uses a tetravalent design protecting against all four serotypes, avoiding antibody-dependent enhancement risk; it will be manufactured domestically by Biological E.

On web, answers are shown once after a test — no save or reattempt. For unlimited reattempts, Hindi medium, and Mentor Observations, use the TAN App.